- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04373564
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (ODYSSEY)
Prospective Evaluation of Potential Effects of Repeated Gadolinium-based Contrast Agent (GBCA) Administrations of the Same GBCA on Motor and Cognitive Functions in Neurologically Normal Adults in Comparison to a Non-GBCA Exposed Control Group
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth.
In this study researchers want to find out whether so called gadolinium-based contrast agents (GBCAs) have an effect on body movement and mental skills when given to participants multiple times within 5 years.
The study plans to enroll about 2076 participants suffering from a condition for which they are likely to have at least annually a MRI or another imaging examinations. Only adults up to 65 years will be considered to join this study. During the study duration of 5 years participants will receive annually a MRI or other imaging tests (such as CT-scan, x-ray) and will visit the study doctor at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills.
Study Overview
Status
Conditions
Detailed Description
The primary objective of the study is to assess the potential effect of repeated exposure to either a linear or a macrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 in composite measure of motor and cognitive function among neurologically normal adults in comparison to a matched non-GBCA- exposed control group.
The secondary objectives comprise the assessment of the following endpoints in GBCA-exposed participants as compared to controls a) changes from baseline in composite measure of motor and cognitive function post-baseline on yearly basis (Years 1 to 4); b) changes from baseline in each individual test of motor and cognitive function on yearly basis (Years 1 to 5). Total Gd concentrations in blood and urine samples on yearly basis (Years 1 to 5) and adverse events will be collected as secondary objectives.
Of note : The study is considered interventional because of the addition of UE-MRI scans for all participants, as well as blood sampling and the administration of the motor and cognitive tests. The GBCA administered as part of the contrast-enhanced MR imaging in the experimental arms is not the intervention in this study. Neither the protocol nor the investigators assign patients to a specific GBCA as part of the study, making this part of the study observational rather than interventional. The participants were already scheduled, prior to study screening, to undergo CE-MRI as part of their clinical care. The choice of GBCA for the CE-MRI will be based on medical need and institutional usage of GBCA, independent of study participation.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jing Hao, MD
- Phone Number: +33647121957
- Email: jing.hao@guerbet.com
Study Contact Backup
- Name: Nathalie LE FUR, PhD
- Phone Number: +33649351166
- Email: nathalie.lefur@guerbet.com
Study Locations
-
-
-
Sao Bernardo Do Campo, Brazil
- Not yet recruiting
- CEMEC - Oncológica
-
Contact:
- Nicole Rabello
- Phone Number: +551143176051
- Email: nicole.rabello@cemecpesquisaclinica.com
-
Principal Investigator:
- Luis Eduardo Werneck de Carvalho, MD
-
-
Distrito Federal
-
Taguatinga, Distrito Federal, Brazil, 72025-110
- Recruiting
- Hospital Santa Marta
-
Contact:
- Ludmila Rufatto Cora Nicastro
- Phone Number: +556139326434
- Email: ludmila.rufatto@ismep.com.br
-
-
RS
-
Passo Fundo, RS, Brazil, 99010-120
- Recruiting
- Instituto Mederi de Pesquisa E Saude
-
Contact:
- Keyla Deucher
- Phone Number: +5549991379921
- Email: keyla.deucher@bioservsmo.com.br
-
Principal Investigator:
- Cassiano Mateus Forcelini, MD
-
Porto Alegre, RS, Brazil, 90035-001
- Recruiting
- Hospital Moinhos de Vento
-
Contact:
- Brenda Santos
- Phone Number: +555133203479
- Email: brenda.santos@hmv.org.br
-
Principal Investigator:
- Guilherme Hohgraefe Neto, MD
-
-
Rio Grande Do Norte
-
Natal, Rio Grande Do Norte, Brazil, 59075-740
- Recruiting
- Liga Norte-Rio-Grandense Contra o Cancer
-
Contact:
- Patricia Moura
- Phone Number: +558440095595
- Email: patricia.pascoto@liga.org.br
-
Principal Investigator:
- Rita de Cassia Simoes Matheus, MD
-
-
SP
-
São José Do Rio Preto, SP, Brazil, 15090-000
- Recruiting
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
-
Contact:
- Luciana Cubas Volpe
- Phone Number: +551732015054
- Email: lucianacubas@gmail.com
-
Principal Investigator:
- Kathia Abdalla
-
São Paulo, SP, Brazil, 01228-200
- Recruiting
- CPCLIN - Centro de Pesquisas Clínicas Ltda.
-
Contact:
- Study Coordinator
- Phone Number: +551127110253
-
Principal Investigator:
- Lis Gomes, MD
-
-
Santa Catarina
-
Florianopolis, Santa Catarina, Brazil, 88020-210
- Recruiting
- Instituto Baía Sul de Ensino e Pesquisa (IEP)
-
Contact:
- Marcela Maria Dutra
- Phone Number: +5548998004664
- Email: marcela.dutra@coris.med.br
-
Principal Investigator:
- Israel Silva Maia, MD
-
-
Sao Paulo
-
São Bernardo do Campo, Sao Paulo, Brazil, 09715-090
- Recruiting
- CEMEC - Oncológica
-
Contact:
- Nicole Rabello
- Phone Number: +551143176051
- Email: nicole.rabello@cemecpesquisaclinica.com
-
Principal Investigator:
- Luis Eduardo Werneck de Carvalho, MD
-
-
-
-
Ontario
-
Burlington, Ontario, Canada, L7N 3V2
- Withdrawn
- G. Kenneth Jansz Medical Professional Corporation
-
-
-
-
-
Siena, Italy, 53100
- Recruiting
- A.O.U. Senese Policlinico Santa Maria alle Scotte
-
Principal Investigator:
- Alfonso Cerase, MD
-
Trieste, Italy, 34125
- Recruiting
- Azienda Ospedaliera Universitaria di Trieste
-
Contact:
- Anna Ianza
- Phone Number: +39403992120
- Email: anna.ianza@asugi.sanita.fvg.it
-
Principal Investigator:
- Alessandra Guglielmi, MD
-
-
-
-
-
Busan, Korea, Republic of, 49241
- Recruiting
- Pusan National University Hospital
-
Principal Investigator:
- Jeong Heo, MD
-
Contact:
- Yun Jung
- Email: yunj555@naver.com
-
Busan, Korea, Republic of, 47392
- Recruiting
- Inje University Busan Paik Hospital
-
Contact:
- Hayun Jung
- Phone Number: +82518908975
- Email: ejjung@busanpaik.ac.kr
-
Principal Investigator:
- Hae Woong Jeong, MD
-
Gwangju, Korea, Republic of, 61453
- Recruiting
- Chosun University Hospital
-
Contact:
- Gyu Won Kim
- Email: nakgp2191@naver.com
-
Principal Investigator:
- JuYeon Cho,, MD
-
Seoul, Korea, Republic of, 06973
- Recruiting
- Chung-Ang University Hospital
-
Contact:
- DaJeong Kwon
- Phone Number: +821029011336
- Email: d5301@caumc.or.kr
-
Principal Investigator:
- Chang-hwan Choi, MD
-
Seoul, Korea, Republic of, 06273
- Recruiting
- Gangnam Severance Hospital, Yonsei University Health System
-
Contact:
- so hyun Kim
- Phone Number: "+82220194608 -0-0000-0000"
- Email: sohyunzang@gmail.com
-
Principal Investigator:
- Joon Jeong, MD
-
-
Gangwon-do
-
Chuncheon, Gangwon-do, Korea, Republic of, 24253
- Recruiting
- Hallym University Chuncheon Sacred Heart Hospital
-
Contact:
- YoungJi Lee
- Phone Number: +82332405645
- Email: yjyj0070@hallym.or.kr
-
Principal Investigator:
- Dong Joon Kim, MD
-
-
Gyeonggi-do
-
Gwangju, Gyeonggi-do, Korea, Republic of, 61469
- Recruiting
- Chonnam National University Hospital
-
Contact:
- Hwasong Lee
- Phone Number: +82622205260
- Email: ghkthddl@naver.com
-
Principal Investigator:
- Sang Soo Shin, MD
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
- Recruiting
- Seoul National University Bundang Hospital
-
Contact:
- JinSil Choi
- Email: rkwkqwe@gmail.com
-
Principal Investigator:
- Won Chang, MD
-
-
-
-
-
Omsk, Russian Federation, 644013
- Suspended
- BHI of Omsk region "Clinical oncology dispensary"
-
Saint-Petersburg, Russian Federation, 192019
- Suspended
- FSBI "National medical scientific center of psychiatry and neurology n.a. V.M. Bekhterev" Adolescent
-
Saint-Petersburg, Russian Federation, 197341
- Suspended
- FSBI North-West Federal Medical Research Center n.a. V.A. Almazov of MoH RF
-
Saint-Petersburg, Russian Federation, 199178
- Suspended
- LLC Medical Center Mart
-
Smolensk, Russian Federation, 214019
- Suspended
- RSBIH "Smolensk Regional Clinical Hospital"
-
Tomsk, Russian Federation, 634009
- Suspended
- Federal State Budgetary Scientific Institution "Tomsk National Research Medical Centre of the Russia
-
Ufa, Russian Federation, 450054
- Suspended
- SBIH Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- Recruiting
- Scottsdale Medical Imaging, LLC
-
Principal Investigator:
- Ronald Korn, MD
-
Contact:
- Phone Number: 480-425-4194
- Email: comrkorn@imagingendpoints.com
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Withdrawn
- Yale University School of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago Medical Center
-
Contact:
- Valentine Mildred
- Phone Number: 773-702-9812
- Email: mvalenti@neurology.bsd.uchicago.edu
-
Principal Investigator:
- Carla Harmath, MD
-
Peoria, Illinois, United States, 61637
- Recruiting
- Methodist Medical Center of Illinois
-
Contact:
- Teresa Osmulski
- Phone Number: 309-672-4808
- Email: teresa.osmulski@unitypoint.org
-
Principal Investigator:
- Praveen Sudhindra, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Beth Israel Deaconess Medical Center
-
Contact:
- Joseph Yap
- Phone Number: 617-667-0325
- Email: jyap1@bidmc.harvard.edu
-
Principal Investigator:
- Leo Tsai, MD
-
Boston, Massachusetts, United States, 02118
- Recruiting
- Boston University Medical Center
-
Contact:
- Phone Number: 617-414-9729
-
Principal Investigator:
- Fishman Michael, MD
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachussets General Hospital
-
Contact:
- Phone Number: 617-726-8396
-
Principal Investigator:
- Mukesh Harisinghani, MD
-
Methuen, Massachusetts, United States, 01844
- Recruiting
- ActivMed Practices & Research, Inc.
-
Principal Investigator:
- Ricardo Sanchez, MD
-
Worcester, Massachusetts, United States, 01655
- Recruiting
- University of Massachusetts Memorial Medical Center
-
Contact:
- Sara Schiller
- Email: sara.schiller1@umassmed.edu
-
Principal Investigator:
- Boris Nicolas Bloch, MD
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Withdrawn
- Department of Radiology
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- UNC School of Medicine
-
Contact:
- Phone Number: 919-966-4292
- Email: lauren_burke@med.unc.edu
-
Principal Investigator:
- Lauren Burke, MD
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Recruiting
- Penn State Hershey Medical Center
-
Contact:
- Rebecca Jordan
- Email: rjordan@pennstatehealth.psu.edu
-
Principal Investigator:
- Nabeel SARWANI, MD
-
Philadelphia, Pennsylvania, United States, 19141
- Recruiting
- Albert Einstein Healthcare Network
-
Contact:
- Meera Kasireddy
- Phone Number: 215-456-6370
- Email: kasiredm@einstein.edu
-
Principal Investigator:
- Ryan Lee, MD
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- UT Southwestern Medical Center
-
Contact:
- Sydney Haldeman Sydney
- Email: sydney.haldeman@utsouthwestern.edu
-
Principal Investigator:
- Takeshi Yokoo, MD
-
Houston, Texas, United States, 77030
- Not yet recruiting
- MD Anderson Cancer Center
-
Contact:
- Riya Nellippallil
- Email: rnellippallil@mdanderson.org
-
Principal Investigator:
- Khaled Elsayes, MD
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- University of Wisconsin
-
Contact:
- Nolan Caroll
- Email: ncarroll@clinicaltrials.wisc.edu
-
Principal Investigator:
- Bruce Richard, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant must be neurologically normal, defined as free of unstable neurologic and psychiatric disease as confirmed by a normal neurologic examination at screening
- Participant (GBCA-exposed or controls) agrees to undergo unenhanced magnetic resonance imaging (UE-MRI) of the brain at enrollment and at the end of the observation period (5 years)
- Participants should have at least 1 of the following indications: a) Medium to high risk for breast cancer or dense breasts undergoing breast cancer screening with MRI, b) Elevated prostate-specific antigen (PSA) and under active diagnostic surveillance for prostate cancer, c) Chronic liver disease (eg, liver cirrhosis limited to Child class A, post-hepatitis chronic hepatopathy, or primary sclerosing cholangitis) for surveillance of hepatocellular carcinoma development, d) Low-grade colorectal cancer or neuroendocrine tumor undergoing screening for liver metastases or e) Branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas (maximum size ≤2 cm) undergoing imaging surveillance.
In addition, for participants in the GBCA Arms only:
- Each participant should be likely to undergo ≥5 GBCA-enhanced MR examinations with the same GBCA at least annually throughout the 5-year study duration
- Prospective participants with up to 3 well documented GBCA administrations prior to study screening are acceptable, provided that the imaging was performed with the same GBCA as the one to be prospectively used in the study. If the GBCA used cannot be identified, he/she cannot be enrolled.
For the Control Arm:
- Participants who never had and are not likely to receive any GBCA injection during the course of the study
- Each control participant must be willing to undergo UE-MRI of the brain at baseline and at Year 5. In Years 1 to 4, the control participants will undergo their clinically indicated UE-MRIs, computed tomography (CT), ultrasound, or X-ray procedures
Exclusion Criteria:
- As evidenced by history or determined in the neurologic exam at screening, concurrent neurological and/or psychiatric disease (or treatments) that could influence the results of the study's motor and cognitive tests (e.g. Cerebrovascular disease, Multiple sclerosis, Neurodegenerative disease, Malignant disease other than listed in indications, Carcinoid tumors, Epilepsy, Prior neurosurgery, Psychotic disorders or any prior psychotic episode not otherwise specified - any documented prior history of chronic schizophrenia, Remittent or current medically confirmed major depressive disorder or bipolar disorder, History of long-term major depression or bipolar affective disorder with an active episode in the past 2 to 5 years, Neurodevelopmental disorders (eg, trisomy 21), Uncontrolled severe migraine, Uncontrolled or controlled anxiety or depression within 6 months before enrollment, Screening scores of ≤24 on the MMSE and/or ≥11 on the Hospital Anxiety and Depression Scale (HADS)).
- Prior, planned, or ongoing chemotherapy or brain irradiation
- Use of concomitant medication(s) affecting neuro-cognitive or motor function
- Substance or alcohol abuse as determined by the investigator
- Alcoholic cirrhosis
- Renal disease, defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2
- History of environmental/occupational/other exposure to one or more chemicals that may affect cognitive and/or motor function, including, but not limited to, heavy metals (arsenic [As], cadmium [Cd], lead [Pb], manganese [Mn], and mercury [Hg]), pesticides, solvents, or carbon monoxide.
- Clinical indications requiring >1 contrast enhanced magnetic resonance imaging (CE-MRI) every 6 months
- Pregnant or nursing (lactating) women
- Presence of any metal-containing joint implants/prostheses
In addition, for participants in either of the GBCA Arms only:
- Receipt of a GBCA or generic prior to study entry other than the specific GBCA to be administered during the course of the study.
For participants in the Control Arm only:
- Participants with any previous exposure to a GBCA.
- Participants with any contraindication to UE-MRI examinations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Linear GBCAs
Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a linear gadoliniumbased contrast agent (GBCA, i.e.
Eovist/ Primovist, MultiHance or Omniscan) prior to MRI.
Each participant will receive the same GBCA throughout the study.
|
To assess motor function annually
To assess cognitive function annually
The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality
Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
Administered as defined by the treating physician as part of routine clinical practice
Other Names:
Administered as defined by the treating physician as part of routine clinical practice
Other Names:
Administered as defined by the treating physician as part of routine clinical practice
Other Names:
|
Experimental: Macrocyclic GBCAs
Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a macrocyclic gadolinium-based contrast agent (GBCA, i.e.
Gadavist/ Gadovist, Dotarem, Magnescope or ProHance) prior to MRI.
Each participant will receive the same GBCA throughout the study.
|
To assess motor function annually
To assess cognitive function annually
The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality
Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
Administered as defined by the treating physician as part of routine clinical practice
Other Names:
Administered as defined by the treating physician as part of routine clinical practice
Other Names:
Administered as defined by the treating physician as part of routine clinical practice
Other Names:
|
Other: No GBCA (Control arm)
Adult participants who were never exposed to any gadolinium-based contrast agent and matching the population characteristics of the two GBCA arms.
They will not receive any gadolinium-based contrast agent over the study course, but may undergo clinically indicated imaging (e.g.
unenhanced magnetic resonance imaging (MRI), unenhanced or enhanced computed tomography, ultrasound and/or X-ray).
|
To assess motor function annually
To assess cognitive function annually
The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality
Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of motor function from baseline to year 5 in comparison to a matched non-GBCA-exposed control group
Time Frame: At baseline, year 5
|
The endpoint is a composite z score, defined as the weighted sum of the z scores of the individual tests
|
At baseline, year 5
|
Change in cognitive function from baseline to year 5 in comparison to a matched non-GBCA-exposed control group
Time Frame: At baseline, year 5
|
The endpoint is a composite z score, defined as the weighted sum of the z scores of the individual tests
|
At baseline, year 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the composite endpoints (motor and cognitive) at each of the post-baseline time points (Years 1 to 4) in GBCA-exposed participants as compared to controls.
Time Frame: At baseline, years 1, 2, 3, 4
|
The endpoint is a composite z score, defined as the weighted sum of the z scores of the individual tests
|
At baseline, years 1, 2, 3, 4
|
Change from baseline for each of the individual tests (motor and cognitive) at each of the post-baseline time points (Years 1 to 5) in GBCA-exposed participants as compared to controls.
Time Frame: At baseline, years 1, 2, 3, 4
|
The endpoint is a composite z score, defined as the weighted sum of the z scores of the individual tests
|
At baseline, years 1, 2, 3, 4
|
Number of participants with adverse events
Time Frame: At baseline, years 1, 2, 3, 4, 5
|
At baseline, years 1, 2, 3, 4, 5
|
|
Total Gd concentrations (as measured in a central laboratory) in blood and urine samples taken from exposed and control participants at the time of the annual visit
Time Frame: At baseline, years 1, 2, 3, 4, 5
|
At baseline, years 1, 2, 3, 4, 5
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Colorectal cancer
- Breast cancer
- Prostate cancer
- Hepatocellular carcinoma
- Gadolinium
- Magnetic Resonance Imaging (MRI)
- Neuroendocrine tumor
- Gadolinium retention
- Motor function assessment
- Cognitive function assessment
- Gadolinium-based contrast agent (GBCA)
- Branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas
Additional Relevant MeSH Terms
Other Study ID Numbers
- DGD-44-065
- 20405 (Bayer)
- GMRA-105 (Other Identifier: Bracco)
- GE-041-081 (Other Identifier: GE Healthcare)
- IQVIA-ODYS-001-LZA45541 (Other Identifier: IQVIA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Function
-
University School of Physical Education in WroclawActive, not recruitingCognitive Function | Executive FunctionPoland
-
Maastricht UniversityWageningen University and Research; Top Institute Food and Nutrition; Netherlands...TerminatedCognitive Function | Ageing | Physical Function | Mitochondrial FunctionNetherlands
-
University Hospital, GenevaCompletedCognitive Function | Falls | Physical FunctionSwitzerland
-
University of FloridaNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedCognitive Function | Older Adults | Physical FunctionUnited States
-
Columbia UniversityNational Institute on Aging (NIA)Terminated
-
Örebro University, SwedenNot yet recruiting
-
Radicle ScienceActive, not recruitingCognitive FunctionUnited States
-
Vanderbilt University Medical CenterCompletedCognitive Function
-
Maastricht University Medical CenterBioActor B.V.Completed
-
University of OstravaCompletedCognitive FunctionCzechia
Clinical Trials on Motor Tests
-
Institut de Myologie, FranceUnknownNeuromuscular DisordersFrance
-
University Hospital, AngersTerminated
-
Istituto Ortopedico RizzoliRecruitingScoliosis Idiopathic | Genu Varum | Flat Feet | Hyperlordosis | Hyperkyphosis | Laxity of Ligament | Genu Valgus | Cavus Foot | Varus; Talipes | Valgus, Talipes | Angular Limb DeformityItaly
-
Loewenstein HospitalWingate InstituteRecruiting
-
Clinica Gema LeonRecruiting
-
Institut de Myologie, FranceRoche Pharma AGNot yet recruitingMuscular Atrophy, Spinal, Type II | Muscular Atrophy, Spinal, Type IIIFrance
-
Riphah International UniversityRecruiting
-
M.D. Anderson Cancer CenterTerminatedBreast CancerUnited States
-
University of PlymouthRecruiting
-
University Ramon LlullAinhoa Nieto Guisado; Mònica Solana-TramuntUnknownCognitive Change | Proprioception Change | Balance ChangeSpain